Compounding-safety group books White House peptide meeting

Forwarded this? Get it weekday mornings: optimized.news/subscribe

Take. Hims has said it will sell peptides if the rules allow it. That makes FDA's peptide plan a marketing problem for every peptide clinic. A national brand bidding on the same search terms makes each new patient more expensive. We'd increase the budget for referrals and retention now, before ad costs climb.

Faegre Drinker Consulting has booked the sixth outside meeting with White House reviewers on the plan, per OIRA's meeting log. The lobbying firm meets Wednesday at 3 p.m. for the Collaborative for Evidence-Based Medicines. CEBM calls itself a provider-led group pushing "safe compounding, and stronger oversight." Its site says it wants to protect patients "from mass-marketed, unapproved compounded drugs." Pharmacist John Hertig chairs its board.

The calendar now has a safety side. CEBM joins the Center for Science in the Public Interest, which meets Tuesday at 2:30 p.m. On the selling side are the American Academy of Peptide Medicine, the Alliance for Pharmacy Compounding and Hims & Hers. Carmen Group meets Wednesday for Medivant Healthcare, a 503B outsourcing facility. No meeting materials have posted.

Hims & Hers had a 2 p.m. slot Friday. Reuters reported Hims shares down 4.5% at $27.82 that day, ahead of the meeting. Reuters noted that Hims has said it plans to offer peptides if the rules allow.

FDA sent the plan to OIRA on Oct. 14 as a notice-stage Interim Access Policy, not a rule. Review under the executive order runs 90 days, to about Jan. 12, with one 30-day extension possible. The first thing to read in the published plan is whether it reaches 503B outsourcing facilities. The conditions attached will decide who can afford to sell.

The FTC sued Hims & Hers in July with Los Angeles County and Utah's consumer protection division. They say Hims shared health data with advertisers while promising discreet care. They also say it billed patients for subscriptions they didn't want. Hims answered with a motion to dismiss, Bloomberg Law reports. The filing argues the complaint ignores a privacy policy "which every visitor to the H&H platform is directed to." It says that policy discloses sharing with ad partners. On billing, Hims argues its plans have no negative-option feature, the trigger for the federal auto-renewal law. Judge Vince Chhabria hears it Thursday, Jan. 7. Most cash-pay clinics run ad pixels and sell multi-month plans. This ruling will show how far a privacy policy and a fixed-term plan protect them. A motion is a request, not a ruling.

U.S. News surveyed more than 1,200 people who used a GLP-1 telehealth platform. Nearly a third had tried more than one. Of those, 57% cited high prices and 36% cited a lack of support. Price is the first reason patients leave. Follow-up is the second. It costs a clinic less to fix.

Mangomint sells booking and payments software to salons and med spas. Its new AI receptionist, Mira, answers calls and texts around the clock, books and reschedules appointments and takes deposits, the company says. It runs only on Mangomint's own phone system. Mangomint doesn't publish the price. Rival Boulevard does: its AI receptionist beta costs $125 a month per location for the first 200 minutes, then 60 cents a minute, per its support page. The software clinics already pay for now wants the front desk too.

Starting in 2027, some employer plans using Cigna's MD Live will give GLP-1 patients an Oura Ring to track doses, meals and side effects.

If this was useful, forward it to a colleague. Hit reply to tell us what you'd like to see more of.

Follow us on X: @optimizednews

Follow ODR on LinkedIn

Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.